Lupus Research Alliance News

January 28, 2022 A large clinical trial led by Harvard Medical School Lupus Program Director Karen H. Costenbader, MD, MPH showed that Vitamin D lowered the risk for autoimmune diseases. The five-year double-blind, placebo-controlled, double-blind trial included more than 25,000 participants.  Fifty one per cent were women; the mean age was 67.1 years. Participants were […] READ MORE

Baricitinib Development as a Lupus Treatment Discontinued

January 28, 2022 The Lupus Research Alliance is disappointed that the Phase 3 development program of  OLUMIANT® (baricitinib) as a potential treatment for adults with systemic lupus erythematosus (SLE) has been discontinued. The drug’s manufacturer Lilly made this decision based on results from two Phase 3 trials (SLE-BRAVE-I and II).  While SLE-BRAVE-I showed a significant […] READ MORE

LRA-Funded Research Uncovers a Novel Pathway to Treat Lupus Nephritis

January 28, 2022 The investigators from The Accelerated Medicines Partnership® Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Program, in collaboration with Drs. Chaim Putterman from the Albert Einstein College of Medicine and Chandra Mohan from the University of Houston, and the biotechnology company Equillium have discovered an immune pathway that plays an important role […] READ MORE

Lupus Research Alliance Launches Two Major Initiatives to Increase Participation of Underrepresented Minorities in Lupus Clinical Trials and Research

January 27, 2022 NEW YORK, NY. January 27 — The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics (LT) announced two major initiatives to address underrepresentation of minorities in clinical trials and in the scientific research profession: Project CHANGE by LT and the Diversity in Lupus Research Program. The organization has tackled these […] READ MORE

Aurinia Announces Positive Long-Term Results on Lupykinis™ for Lupus Nephritis

December 9, 2021 The LRA is pleased to share positive topline three-year efficacy and safety results reported today by Aurinia Pharmaceuticals from the AURORA 2 continuation study of Lupkynis™ (voclosporin). These results provide the longest available data for an FDA-approved medicine in lupus nephritis. The U.S. Food and Drug Administration approved Lupkynis arlier this year […] READ MORE

LRA Partnering with NIH, FNIH and Others on Groundbreaking Initiative

December 9, 2021 The Lupus Research Alliance (LRA) is proud and excited to partner again with the National Institutes of Health (NIH), the Foundation for the National Institutes of Health (FNIH), and others on a new program – Accelerating Medicines Partnership® Autoimmune and Immune-Mediated Diseases (AMP® AIM) – that will apply new cutting-edge tools to […] READ MORE

Thanks To NY JETS for Hosting LUPUS AWARENESS DAY November 21

November 22, 2021 The New York Jets and Lupus Research Alliance (LRA) hosted Lupus Awareness Day on November 21, 2021, at MetLife Stadium, with the Jets taking on their division rivals the Miami Dolphins. The event raised awareness of the devastating autoimmune disease and generated over $25,000 for lupus research. The check was accepted by […] READ MORE

2021 Breaking Through Gala

This year the Lupus Research Alliance Breaking Through Gala will take place the evening of Monday, November 22, 2021 both in person and online! So whether you’ll be joining us in New York City at the Ziegfeld Ballroom or watching our live broadcast online, you can support the promising research that is breaking through the […] READ MORE

Pivotal LRA-Funded Research Shared at Annual Rheumatology Meeting

November 15, 2021 The Lupus Research Alliance (LRA) supports research into causes and mechanisms of lupus, and identification of targets supporting the development of new therapies or cures for lupus patients. At this year’s meeting of the American College of Rheumatology (ACR), 17 LRA-funded researchers presented their work to share discoveries with the thousands of […] READ MORE

Learn and connect with our community!